Trials / Unknown
UnknownNCT00604760
Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
A Phase 2a, Multi-Center, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of MEM 3454 as Adjunctive Treatment in Combination With a Preexisting Antipsychotic in Patients With Cognitive Impairment Associated With Schizophrenia
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Memory Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
To establish the proof of concept that MEM 3454, used as add-on pharmacotherapy, is a safe and effective treatment in patients with cognitive impairment associated with schizophrenia (CIAS).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEM 3454 | Capsule 5 mg once a day |
| DRUG | MEM 3454 | Capsule 15 mg once a day |
| DRUG | MEM 3454 | Capsule 50 mg once a day |
| DRUG | Placebo for MEM 3454 | Capsule once a day |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2009-02-01
- First posted
- 2008-01-30
- Last updated
- 2008-12-08
Locations
44 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00604760. Inclusion in this directory is not an endorsement.